tag physician-practices 
Rethinking Clinical Trials
JULY 13, 2023
Patients went through a screening by a study physician for eligibility. The physician-pharmacist team developed recommendations using an algorithm that was supported by the ACC, AHA clinical practice guidelines. Speaker Ankeet S. Bhatt, MD, MBA, ScM) appeared first on Rethinking Clinical Trials.
Rethinking Clinical Trials
DECEMBER 12, 2023
Discussion Themes -Within individual physicians, did you see an increase in goals of care discussions? We have not looked within clinician practices for documentation. What’s hard is that patients have a number of different physicians. We don’t have much data on the overall effect on individual physicians behavior.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JULY 12, 2021
“Based on our ongoing conversations with prescribing physicians, FDA and patient advocates, we submitted this label update with the goal to further clarify the patient population that was studied across the three Aduhelm clinical trials that supported approval. head of research and development at Biogen, in a statement from the company.
Rethinking Clinical Trials
MARCH 21, 2023
Goldberg Distinguished Professor and Chief of Oncology Physician-in-Chief, North Carolina Cancer Hospital Director, Cancer Outcomes Research Program University of North Carolina Slides Keywords Patient-reported outcomes, Oncology, Clinical Trials Key Points Symptoms are common in cancer care. community oncology practices across 25 states.
Rethinking Clinical Trials
AUGUST 28, 2023
The American College of Physicians guideline states that “physicians and patients should treat acute, sub-acute and chronic LBP with non-drug therapies.” We are learning together in real-time because we are trying to change how people think about clinical practice for low back pain. That is a real challenge.
XTalks
JANUARY 19, 2024
Briner, known as the father of radiopharmacy, having paved the way for its practice, the use of radiopharmaceuticals in medicine continues to grow and evolve. However, for alpha emitter therapies, practices are not yet standardized for normal tissue tolerances and dosimetry.
Pharma Marketing Network
JUNE 8, 2020
I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.
Expert insights. Personalized for you.
130 
Let's personalize your content